BioElectronics enters Mexican market:
This article was originally published in Clinica
Executive Summary
BioElectronics (Frederick, Maryland) has announced a distribution agreement with Mexican firm Eximeq to introduce its ActiPatch technology to the latter's domestic market. ActiPatch is a drug-free, anti-inflammatory device with embedded microchip technology that administers weeks of continuous pulsed tissue therapy to treat swelling, pain and soft and hard tissue injuries for less than a dollar a day. BioElectronics claims that ActiPatch has been clinically proven to reduce swelling and bruising by 50%.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.